Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C

Mitchell L. Shiffman, Marc G. Ghany, Timothy R. Morgan, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S F Lok, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, David R. Gretch

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Background & Aims: Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. Methods: Nine hundred thirty-six patients with chronic hepatitis C genotype 1, advanced fibrosis, or cirrhosis (Ishak 3-6) and prior nonresponse to standard interferon ± ribavirin were retreated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) during the lead-in phase of the HALT-C trial. The percentage of each medication actually taken during treatment was calculated. Results: Reducing the total cumulative dose of peginterferon received during the first 20 weeks of treatment from full dose (≥98%) to ≤60% reduced week 20 virologic response (W20 VR) from 35% to 12% and SVR from 17% to 5%. Reducing the dose of ribavirin from full dose (≥98%) to ≤60% did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days. Prematurely discontinuing ribavirin, even at full-dose peginterferon, reduced W20 VR to ≤19% and SVR to ≤4%. Conclusions: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR. In contrast, reducing ribavirin did not affect either W20 VR or SVR as long as patients remained on full-dose peginterferon. Discontinuing ribavirin prematurely was associated with a marked decline in both VR and SVR.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalGastroenterology
Volume132
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Retreatment
Ribavirin
Chronic Hepatitis C
Fibrosis
peginterferon alfa-2a
Therapeutics
Sustained Virologic Response
Hepacivirus
Interferons
Genotype

Keywords

  • chronic hepatitis C virus
  • early virologic response
  • end-of-treatment
  • EOT
  • EVR
  • HALT-C
  • HCV
  • Hepatitis Antiviral Long-term Treatment Against Cirrhosis
  • sustained virologic response
  • SVR
  • virologic response
  • VR
  • W20 VR
  • W72
  • week 20 virologic response
  • week 72

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Shiffman, M. L., Ghany, M. G., Morgan, T. R., Wright, E. C., Everson, G. T., Lindsay, K. L., ... Gretch, D. R. (2007). Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology, 132(1), 103-112. https://doi.org/10.1053/j.gastro.2006.11.011

Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. / Shiffman, Mitchell L.; Ghany, Marc G.; Morgan, Timothy R.; Wright, Elizabeth C.; Everson, Gregory T.; Lindsay, Karen L.; Lok, Anna S F; Bonkovsky, Herbert L.; Di Bisceglie, Adrian M.; Lee, William M.; Dienstag, Jules L.; Gretch, David R.

In: Gastroenterology, Vol. 132, No. 1, 01.2007, p. 103-112.

Research output: Contribution to journalArticle

Shiffman, ML, Ghany, MG, Morgan, TR, Wright, EC, Everson, GT, Lindsay, KL, Lok, ASF, Bonkovsky, HL, Di Bisceglie, AM, Lee, WM, Dienstag, JL & Gretch, DR 2007, 'Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C', Gastroenterology, vol. 132, no. 1, pp. 103-112. https://doi.org/10.1053/j.gastro.2006.11.011
Shiffman, Mitchell L. ; Ghany, Marc G. ; Morgan, Timothy R. ; Wright, Elizabeth C. ; Everson, Gregory T. ; Lindsay, Karen L. ; Lok, Anna S F ; Bonkovsky, Herbert L. ; Di Bisceglie, Adrian M. ; Lee, William M. ; Dienstag, Jules L. ; Gretch, David R. / Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. In: Gastroenterology. 2007 ; Vol. 132, No. 1. pp. 103-112.
@article{e6b63799796d4e099c7e6848417ee157,
title = "Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C",
abstract = "Background & Aims: Reducing the dose of peginterferon and/or ribavirin to <80{\%} when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. Methods: Nine hundred thirty-six patients with chronic hepatitis C genotype 1, advanced fibrosis, or cirrhosis (Ishak 3-6) and prior nonresponse to standard interferon ± ribavirin were retreated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) during the lead-in phase of the HALT-C trial. The percentage of each medication actually taken during treatment was calculated. Results: Reducing the total cumulative dose of peginterferon received during the first 20 weeks of treatment from full dose (≥98{\%}) to ≤60{\%} reduced week 20 virologic response (W20 VR) from 35{\%} to 12{\%} and SVR from 17{\%} to 5{\%}. Reducing the dose of ribavirin from full dose (≥98{\%}) to ≤60{\%} did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days. Prematurely discontinuing ribavirin, even at full-dose peginterferon, reduced W20 VR to ≤19{\%} and SVR to ≤4{\%}. Conclusions: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR. In contrast, reducing ribavirin did not affect either W20 VR or SVR as long as patients remained on full-dose peginterferon. Discontinuing ribavirin prematurely was associated with a marked decline in both VR and SVR.",
keywords = "chronic hepatitis C virus, early virologic response, end-of-treatment, EOT, EVR, HALT-C, HCV, Hepatitis Antiviral Long-term Treatment Against Cirrhosis, sustained virologic response, SVR, virologic response, VR, W20 VR, W72, week 20 virologic response, week 72",
author = "Shiffman, {Mitchell L.} and Ghany, {Marc G.} and Morgan, {Timothy R.} and Wright, {Elizabeth C.} and Everson, {Gregory T.} and Lindsay, {Karen L.} and Lok, {Anna S F} and Bonkovsky, {Herbert L.} and {Di Bisceglie}, {Adrian M.} and Lee, {William M.} and Dienstag, {Jules L.} and Gretch, {David R.}",
year = "2007",
month = "1",
doi = "10.1053/j.gastro.2006.11.011",
language = "English (US)",
volume = "132",
pages = "103--112",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C

AU - Shiffman, Mitchell L.

AU - Ghany, Marc G.

AU - Morgan, Timothy R.

AU - Wright, Elizabeth C.

AU - Everson, Gregory T.

AU - Lindsay, Karen L.

AU - Lok, Anna S F

AU - Bonkovsky, Herbert L.

AU - Di Bisceglie, Adrian M.

AU - Lee, William M.

AU - Dienstag, Jules L.

AU - Gretch, David R.

PY - 2007/1

Y1 - 2007/1

N2 - Background & Aims: Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. Methods: Nine hundred thirty-six patients with chronic hepatitis C genotype 1, advanced fibrosis, or cirrhosis (Ishak 3-6) and prior nonresponse to standard interferon ± ribavirin were retreated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) during the lead-in phase of the HALT-C trial. The percentage of each medication actually taken during treatment was calculated. Results: Reducing the total cumulative dose of peginterferon received during the first 20 weeks of treatment from full dose (≥98%) to ≤60% reduced week 20 virologic response (W20 VR) from 35% to 12% and SVR from 17% to 5%. Reducing the dose of ribavirin from full dose (≥98%) to ≤60% did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days. Prematurely discontinuing ribavirin, even at full-dose peginterferon, reduced W20 VR to ≤19% and SVR to ≤4%. Conclusions: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR. In contrast, reducing ribavirin did not affect either W20 VR or SVR as long as patients remained on full-dose peginterferon. Discontinuing ribavirin prematurely was associated with a marked decline in both VR and SVR.

AB - Background & Aims: Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. Methods: Nine hundred thirty-six patients with chronic hepatitis C genotype 1, advanced fibrosis, or cirrhosis (Ishak 3-6) and prior nonresponse to standard interferon ± ribavirin were retreated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) during the lead-in phase of the HALT-C trial. The percentage of each medication actually taken during treatment was calculated. Results: Reducing the total cumulative dose of peginterferon received during the first 20 weeks of treatment from full dose (≥98%) to ≤60% reduced week 20 virologic response (W20 VR) from 35% to 12% and SVR from 17% to 5%. Reducing the dose of ribavirin from full dose (≥98%) to ≤60% did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days. Prematurely discontinuing ribavirin, even at full-dose peginterferon, reduced W20 VR to ≤19% and SVR to ≤4%. Conclusions: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR. In contrast, reducing ribavirin did not affect either W20 VR or SVR as long as patients remained on full-dose peginterferon. Discontinuing ribavirin prematurely was associated with a marked decline in both VR and SVR.

KW - chronic hepatitis C virus

KW - early virologic response

KW - end-of-treatment

KW - EOT

KW - EVR

KW - HALT-C

KW - HCV

KW - Hepatitis Antiviral Long-term Treatment Against Cirrhosis

KW - sustained virologic response

KW - SVR

KW - virologic response

KW - VR

KW - W20 VR

KW - W72

KW - week 20 virologic response

KW - week 72

UR - http://www.scopus.com/inward/record.url?scp=33846356749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846356749&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2006.11.011

DO - 10.1053/j.gastro.2006.11.011

M3 - Article

VL - 132

SP - 103

EP - 112

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -